- Home
- SGU vs NPCE Comparison
SGU vs NPCE Comparison
Compare SGU & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- NPCE
- Stock Information
- Founded
- SGU 1995
- NPCE 1997
- Country
- SGU United States
- NPCE United States
- Employees
- SGU N/A
- NPCE N/A
- Industry
- SGU Other Specialty Stores
- NPCE Medical Specialities
- Sector
- SGU Consumer Discretionary
- NPCE Health Care
- Exchange
- SGU Nasdaq
- NPCE Nasdaq
- Market Cap
- SGU 390.2M
- NPCE 342.7M
- IPO Year
- SGU 1995
- NPCE 2021
- Fundamental
- Price
- SGU N/A
- NPCE $10.82
- Analyst Decision
- SGU
- NPCE Strong Buy
- Analyst Count
- SGU 0
- NPCE 6
- Target Price
- SGU N/A
- NPCE $16.67
- AVG Volume (30 Days)
- SGU 31.9K
- NPCE 149.8K
- Earning Date
- SGU 12-03-2025
- NPCE 11-11-2025
- Dividend Yield
- SGU 6.34%
- NPCE N/A
- EPS Growth
- SGU 33.71
- NPCE N/A
- EPS
- SGU 1.66
- NPCE N/A
- Revenue
- SGU $1,777,057,000.00
- NPCE $88,570,000.00
- Revenue This Year
- SGU N/A
- NPCE $22.13
- Revenue Next Year
- SGU N/A
- NPCE $6.07
- P/E Ratio
- SGU $7.05
- NPCE N/A
- Revenue Growth
- SGU N/A
- NPCE 23.32
- 52 Week Low
- SGU $10.84
- NPCE $5.45
- 52 Week High
- SGU $13.75
- NPCE $18.98
- Technical
- Relative Strength Index (RSI)
- SGU 49.20
- NPCE 57.95
- Support Level
- SGU $11.68
- NPCE $10.25
- Resistance Level
- SGU $11.90
- NPCE $11.25
- Average True Range (ATR)
- SGU 0.18
- NPCE 0.50
- MACD
- SGU -0.00
- NPCE -0.02
- Stochastic Oscillator
- SGU 44.07
- NPCE 65.44
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.